JP2016529284A - ナノ粒子薬物デリバリシステムおよび、癌および神経外傷の治療方法 - Google Patents

ナノ粒子薬物デリバリシステムおよび、癌および神経外傷の治療方法 Download PDF

Info

Publication number
JP2016529284A
JP2016529284A JP2016537829A JP2016537829A JP2016529284A JP 2016529284 A JP2016529284 A JP 2016529284A JP 2016537829 A JP2016537829 A JP 2016537829A JP 2016537829 A JP2016537829 A JP 2016537829A JP 2016529284 A JP2016529284 A JP 2016529284A
Authority
JP
Japan
Prior art keywords
formulation
olaparib
lipid
parp
parp inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016537829A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016529284A5 (cg-RX-API-DMAC7.html
Inventor
タングテューリ，シャファリカ
スリデゥハ，スリニヴァス
Original Assignee
ノースイースタン ユニバーシティ
ノースイースタン ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノースイースタン ユニバーシティ, ノースイースタン ユニバーシティ filed Critical ノースイースタン ユニバーシティ
Publication of JP2016529284A publication Critical patent/JP2016529284A/ja
Publication of JP2016529284A5 publication Critical patent/JP2016529284A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016537829A 2013-08-27 2014-08-27 ナノ粒子薬物デリバリシステムおよび、癌および神経外傷の治療方法 Pending JP2016529284A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361870258P 2013-08-27 2013-08-27
US61/870,258 2013-08-27
PCT/US2014/053006 WO2015031536A1 (en) 2013-08-27 2014-08-27 Nanoparticle drug delivery system and method of treating cancer and neurotrauma

Publications (2)

Publication Number Publication Date
JP2016529284A true JP2016529284A (ja) 2016-09-23
JP2016529284A5 JP2016529284A5 (cg-RX-API-DMAC7.html) 2017-10-05

Family

ID=52587308

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016537829A Pending JP2016529284A (ja) 2013-08-27 2014-08-27 ナノ粒子薬物デリバリシステムおよび、癌および神経外傷の治療方法

Country Status (4)

Country Link
US (1) US10111871B2 (cg-RX-API-DMAC7.html)
EP (1) EP3038600B1 (cg-RX-API-DMAC7.html)
JP (1) JP2016529284A (cg-RX-API-DMAC7.html)
WO (1) WO2015031536A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022536708A (ja) * 2019-06-12 2022-08-18 リーベン アイピー ホールディングカンパニー リミテッド ライアビリティ カンパニー がん患者の予後を改善する方法および組成物

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
AU2016281622C1 (en) * 2015-06-25 2021-11-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
SG10201913073YA (en) 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
US20170049775A1 (en) 2015-08-21 2017-02-23 Merrimack Pharmaceuticals, Inc. Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
CN114099437A (zh) 2015-10-16 2022-03-01 易普森生物制药有限公司 稳定喜树碱药物组合物
EP3411027A1 (en) * 2016-02-01 2018-12-12 AbbVie Inc. Extended release formulations of veliparib for the treatment of cancer
GB201608885D0 (en) * 2016-05-20 2016-07-06 Univ Birmingham Treatment
CN107951861B (zh) * 2016-10-17 2020-12-01 南京绿叶制药有限公司 一种脂质纳米粒膜材料组合物
RU2761953C2 (ru) 2016-11-02 2021-12-14 Ипсен Биофарм Лтд. Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин)
CN108201536A (zh) * 2016-12-16 2018-06-26 中国科学院上海药物研究所 一种奥拉帕尼口服缓控释药物组合物及其用途
CN108201534A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种瑞卡帕布口服缓控释药物组合物及其用途
CN108201535A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种维利帕尼缓控释药物组合物及其用途
EP3610859A4 (en) * 2017-04-12 2021-01-27 Beijing Inno Medicine Co., Ltd. CERASOM DELIVERY SYSTEM FOR USE IN THE TARGETED ACTIVATION OF CD44 MOLECULES, MANUFACTURING METHOD FOR IT AND USE
WO2019200382A1 (en) * 2018-04-13 2019-10-17 The Board Of Regents Of University Of Texas System Nanoparticle compositions and methods of use of parp inhibitor for treatment of cancer
KR102017115B1 (ko) * 2018-05-15 2019-09-02 충남대학교산학협력단 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물
US11648211B2 (en) * 2019-09-23 2023-05-16 Northeastern University Nanoencapsulated combination drug formulations
CN111187416A (zh) * 2020-01-17 2020-05-22 广州古泉生物科技有限公司 一种壳聚糖-g-聚ε-己内酯衍生物载药纳米胶束的制备方法和应用
WO2022115207A1 (en) * 2020-11-25 2022-06-02 Trustees Of Dartmouth College Method for attenuating neuroinflammation
PL438742A1 (pl) * 2021-08-14 2023-02-20 Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością Liposom kationowy wiążący i stabilizujący RNA, jego zastosowanie i sposób ładowania liposomu emetyną
EP4429636A1 (en) * 2021-11-10 2024-09-18 Crititech, Inc. Rucaparib particles and uses thereof
WO2023191628A1 (en) 2022-03-30 2023-10-05 Bioneedle Drug Delivery B.V. A process for storing biologically active constructs in a biodegradable material
CN116297044A (zh) * 2022-12-07 2023-06-23 浙江萃泽医药科技有限公司 一种糠酸莫米松鼻喷雾剂中微晶纤维素粒径的测试方法
WO2025024581A1 (en) * 2023-07-24 2025-01-30 University Of Maryland, College Park Parp-inhibitor nanoparticles and methods thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001026544A (ja) * 1999-05-11 2001-01-30 Sankyo Co Ltd 脂溶性抗腫瘍薬のリポソーム製剤
KR20090013848A (ko) * 2007-08-03 2009-02-06 한국화학연구원 안트라사이클라인계 항암약물 봉입용 리포솜 및 이의제조방법
WO2009096487A1 (ja) * 2008-01-30 2009-08-06 The University Of Tokushima オキサリプラチンリポソーム製剤からなる抗腫瘍効果増強剤及び当該リポソーム製剤を含有する抗腫瘍剤
US20100104629A1 (en) * 2008-04-16 2010-04-29 Abbott Laboratories Cationic lipids and uses thereof
WO2012031205A2 (en) * 2010-09-03 2012-03-08 The Brigham And Women's Hospital, Inc. Lipid-polymer hybrid particles

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3032004B2 (ja) 1989-06-23 2000-04-10 ザ リポソーム カンパニー，インコーポレイテッド 標的化リポソーム及びリポソーム―蛋白質カップリング方法
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
NL9000207A (cg-RX-API-DMAC7.html) 1990-01-29 1991-08-16 Duphar Int Res
JPH07509250A (ja) 1992-07-27 1995-10-12 アメリカ合衆国 血液脳バリヤーへのリポソームの標的化
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US6635642B1 (en) * 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US7037520B2 (en) * 2002-03-22 2006-05-02 Baylor College Of Medicine Reversible masking of liposomal complexes for targeted delivery
JP2008527002A (ja) * 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物
US20090220587A1 (en) 2005-02-01 2009-09-03 United State Army Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands
JP2010505880A (ja) * 2006-10-06 2010-02-25 ポリテクニック、インスティチュート、オブ、ニューヨーク、ユニバーシティー ｐＨ感受性リポソーム組成物
JP2010520855A (ja) 2007-01-31 2010-06-17 アフィーマックス・インコーポレイテッド 修飾基をポリペプチドおよびその他の高分子に結合するための窒素ベースのリンカー
WO2008139804A1 (ja) * 2007-05-14 2008-11-20 Ltt Bio-Pharma Co., Ltd. 徐放性の陰荷電基を持つ低分子薬物含有ナノ粒子
US20110233079A1 (en) * 2009-06-30 2011-09-29 Macinnes Susan E Medical Kit, Packaging System, Instruction Insert, and Associated Methods
WO2009129387A2 (en) 2008-04-16 2009-10-22 Abbott Laboratories Cationic lipids and uses thereof
US20110123451A1 (en) 2009-11-21 2011-05-26 Max Kullberg Method for Cell Delivery Using Targeted Liposomes Associated with a Hemolysin
EP2533640B1 (en) 2010-02-08 2016-09-28 Medivation Technologies, Inc. Processes of synthesizing dihydropyridophthalazinone derivatives
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001026544A (ja) * 1999-05-11 2001-01-30 Sankyo Co Ltd 脂溶性抗腫瘍薬のリポソーム製剤
KR20090013848A (ko) * 2007-08-03 2009-02-06 한국화학연구원 안트라사이클라인계 항암약물 봉입용 리포솜 및 이의제조방법
WO2009096487A1 (ja) * 2008-01-30 2009-08-06 The University Of Tokushima オキサリプラチンリポソーム製剤からなる抗腫瘍効果増強剤及び当該リポソーム製剤を含有する抗腫瘍剤
US20100104629A1 (en) * 2008-04-16 2010-04-29 Abbott Laboratories Cationic lipids and uses thereof
WO2012031205A2 (en) * 2010-09-03 2012-03-08 The Brigham And Women's Hospital, Inc. Lipid-polymer hybrid particles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BLANCO, MD., ET. AL., "CHAPTER 9: TARGETED NANOPARRICLES FOR CANCER THERAPY", RECENT ADVANCES IN NOVEL DRUG CARRIER SYSTEM, JPN6018022118, ISSN: 0003967431 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022536708A (ja) * 2019-06-12 2022-08-18 リーベン アイピー ホールディングカンパニー リミテッド ライアビリティ カンパニー がん患者の予後を改善する方法および組成物

Also Published As

Publication number Publication date
EP3038600B1 (en) 2020-06-03
EP3038600A1 (en) 2016-07-06
US20160206615A1 (en) 2016-07-21
EP3038600A4 (en) 2017-03-01
US10111871B2 (en) 2018-10-30
WO2015031536A1 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
US10111871B2 (en) Nanoparticle drug delivery system and method of treating cancer and neurotrauma
Iturrioz-Rodríguez et al. Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment
Wang et al. Enhanced tumor delivery and antitumor activity in vivo of liposomal doxorubicin modified with MCF-7-specific phage fusion protein
Zhang et al. Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy
Zhang et al. Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy
Lu et al. Afatinib-loaded immunoliposomes functionalized with cetuximab: A novel strategy targeting the epidermal growth factor receptor for treatment of non-small-cell lung cancer
US11648211B2 (en) Nanoencapsulated combination drug formulations
CN117159470A (zh) 脂质体包封的亲和性药物
JP2010180210A (ja) 併用薬剤を送達するための組成物
US20230172856A1 (en) Liposome formulations for treatment of cancers and drug resistance of cancers
Han et al. Therapeutic efficacy of doxorubicin delivery by a CO2 generating liposomal platform in breast carcinoma
US11969396B2 (en) IPA-3-loaded liposomes and methods of use thereof
Kumar et al. Polymeric nanomedicine for overcoming resistance mechanisms in hedgehog and Myc-amplified medulloblastoma
WO2008038291A1 (en) Combination of liposomal anti-cancer drugs and lysosome/endosome ph increasing agents for therapy
Orthmann et al. Improved treatment of MT-3 breast cancer and brain metastases in a mouse xenograft by LRP-targeted oxaliplatin liposomes
Gupta et al. Lipid-based nanocarriers in the treatment of glioblastoma multiforme (GBM): challenges and opportunities
Behl et al. Nano-based drug delivery of anticancer chemotherapeutic drugs targeting breast cancer
US20130164379A1 (en) Nanoparticle micelle coated compositions
WO2018019284A1 (en) Compounds for enhancing bax/bcl-2 expression and activity and therapeutic use thereof
Gutierrez et al. Photochemical internalization with verteporfin-liposomes enhances oxaliplatin retention and efficacy in models of pancreatic cancer
CN106061470A (zh) 含有多种物质的聚合物纳米粒子及其方法
Wang et al. ang,.(2025)
US20220118116A1 (en) Adhesive/adsorption switch on nanoparticles to increase tumor uptake and delay tumor clearance
Baldwin¹ et al. for Treatment of Ewing Sarcoma
Arsiwala Multifunctional Liposomal Carriers Encapsulating Temozolomide, RG7388 and Elacridar for Targeted Glioblastoma Multiforme Therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170828

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180619

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190205